@article {7975,
	title = {Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma},
	journal = {Haematologica},
	volume = {91},
	year = {2006},
	note = {Cited By :37Export Date: 21 February 2017},
	month = {2006},
	pages = {252 - 254},
	abstract = {Fifty patients with multiple myeloma >=75 years of age received primary treatment with melphalan (M) 8 mg/m2 on days 1-4, dexamethasone (D) 12 mg/m2 on days 1-4 and 17-20 and thalidomide (T) 300 mg at bedtime on days 1-4 and 17-20. This regimen was repeated every 5 weeks for three courses. Patients without evidence of disease progression received nine additional courses of MDT, but without DT on days 17-20, every 5 weeks. Sixty-two percent of patients achieved a partial response and 10\% a complete response. The median time to response was 2 months. The median time to progression for all patients was 21.2 months. Deep venous thrombosis and peripheral neuropathy each occurred in 9\% of patients. {\textcopyright}2006 Ferrata Storti Foundation.},
	keywords = {Elderly, multiple myeloma, Thalidomide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644533213\&partnerID=40\&md5=2e48899d0d662de9f7d5a199b4f2835c},
	author = {Dimopoulos, M.A. and Anagnostopoulos, A. and Terpos, E. and Repoussis, P. and Zomas, A. and Katodritou, E. and Kyrtsonis, M.C. and Delibasi, S. and Vassou, A. and Pouli, A. and Zervas, K. and Anagnostopoulos, N. and Maniatis, A.}
}
